Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Sep 2025 value amounting to $133.8 million.

  • Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) rose 11.67% to $133.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.8 million, marking a year-over-year increase of 11.67%. This contributed to the annual value of $133.8 million for FY2025, which is 11.67% up from last year.
  • According to the latest figures from FY2025, Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) is $133.8 million, which was up 11.67% from $119.8 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $133.8 million in FY2025 and a low of $103.7 million during FY2021.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $119.8 million (recorded in 2024), while the average stood at $120.1 million.
  • Data for Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY rose of 12.21% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Arrowhead Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $103.7 million in 2021, then climbed by 1.62% to $105.4 million in 2022, then grew by 1.26% to $106.8 million in 2023, then increased by 12.21% to $119.8 million in 2024, then grew by 11.67% to $133.8 million in 2025.